@article{e7732d06fd0445d9b04e6630d268bc2f,
title = "Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium difficile Infection",
abstract = "We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged ≥65 years and with severe CDI. Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).",
keywords = "C. difficile infection, bezlotoxumab, hospital readmissions, recurrence",
author = "Prabhu, {Vimalanand S.} and Cornely, {Oliver A.} and Yoav Golan and Dubberke, {Erik R.} and Heimann, {Sebastian M.} and Hanson, {Mary E.} and Jane Liao and Alison Pedley and Dorr, {Mary Beth} and Stephen Marcella",
note = "Funding Information: Financial support. This work was supported by Merck & Co., Inc., Kenilworth, NJ. Publisher Copyright: {\textcopyright} The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.",
year = "2017",
month = oct,
day = "1",
doi = "10.1093/cid/cix523",
language = "English",
volume = "65",
pages = "1218--1221",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
number = "7",
}